These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 29097420)

  • 1. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
    Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
    Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral CD8
    Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
    Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.
    Hoves S; Ooi CH; Wolter C; Sade H; Bissinger S; Schmittnaegel M; Ast O; Giusti AM; Wartha K; Runza V; Xu W; Kienast Y; Cannarile MA; Levitsky H; Romagnoli S; De Palma M; Rüttinger D; Ries CH
    J Exp Med; 2018 Mar; 215(3):859-876. PubMed ID: 29436396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
    Pham CD; Flores C; Yang C; Pinheiro EM; Yearley JH; Sayour EJ; Pei Y; Moore C; McLendon RE; Huang J; Sampson JH; Wechsler-Reya R; Mitchell DA
    Clin Cancer Res; 2016 Feb; 22(3):582-95. PubMed ID: 26405194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.
    Sanders KL; Fox BA; Bzik DJ
    Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
    Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM
    J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
    Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
    Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Shayan G; Kansy BA; Gibson SP; Srivastava RM; Bryan JK; Bauman JE; Ohr J; Kim S; Duvvuri U; Clump DA; Heron DE; Johnson JT; Hershberg RM; Ferris RL
    Clin Cancer Res; 2018 Jan; 24(1):62-72. PubMed ID: 29061643
    [No Abstract]   [Full Text] [Related]  

  • 14. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
    Polesso F; Weinberg AD; Moran AE
    Cancer Immunol Res; 2019 Feb; 7(2):269-281. PubMed ID: 30563828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophages and CD8
    Zhang JQ; Zeng S; Vitiello GA; Seifert AM; Medina BD; Beckman MJ; Loo JK; Santamaria-Barria J; Maltbaek JH; Param NJ; Moral JA; Zhao JN; Balachandran V; Rossi F; Antonescu CR; DeMatteo RP
    Cancer Immunol Res; 2018 Apr; 6(4):434-447. PubMed ID: 29467128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.
    Dovedi SJ; Lipowska-Bhalla G; Beers SA; Cheadle EJ; Mu L; Glennie MJ; Illidge TM; Honeychurch J
    Cancer Immunol Res; 2016 Jul; 4(7):621-630. PubMed ID: 27241845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
    Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
    Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.